Literature DB >> 29538733

Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis.

Carsten Schwarz1, Patrick Vandeputte2,3, Amandine Rougeron4, Sandrine Giraud2, Thomas Dugé de Bernonville5, Ludovic Duvaux2,6, Amandine Gastebois2, Ana Alastruey-Izquierdo7, Maria Teresa Martín-Gomez8, Estrella Martin Mazuelos9, Amparo Sole10, Josep Cano11, Javier Pemán12, Guillermo Quindos13, Françoise Botterel14, Marie-Elisabeth Bougnoux15, Sharon Chen16, Laurence Delhaès17, Loïc Favennec18, Stéphane Ranque19, Ludwig Sedlacek20, Joerg Steinmann21, Jose Vazquez22, Craig Williams23, Wieland Meyer24, Solène Le Gal25,26, Gilles Nevez25,26, Maxime Fleury2, Nicolas Papon2, Françoise Symoens2, Jean-Philippe Bouchara2,3.   

Abstract

Cystic fibrosis (CF) is the major genetic inherited disease in Caucasian populations. The respiratory tract of CF patients displays a sticky viscous mucus, which allows for the entrapment of airborne bacteria and fungal spores and provides a suitable environment for growth of microorganisms, including numerous yeast and filamentous fungal species. As a consequence, respiratory infections are the major cause of morbidity and mortality in this clinical context. Although bacteria remain the most common agents of these infections, fungal respiratory infections have emerged as an important cause of disease. Therefore, the International Society for Human and Animal Mycology (ISHAM) has launched a working group on Fungal respiratory infections in Cystic Fibrosis (Fri-CF) in October 2006, which was subsequently approved by the European Confederation of Medical Mycology (ECMM). Meetings of this working group, comprising both clinicians and mycologists involved in the follow-up of CF patients, as well as basic scientists interested in the fungal species involved, provided the opportunity to initiate collaborative works aimed to improve our knowledge on these infections to assist clinicians in patient management. The current review highlights the outcomes of some of these collaborative works in clinical surveillance, pathogenesis and treatment, giving special emphasis to standardization of culture procedures, improvement of species identification methods including the development of nonculture-based diagnostic methods, microbiome studies and identification of new biological markers, and the description of genotyping studies aiming to differentiate transient carriage and chronic colonization of the airways. The review also reports on the breakthrough in sequencing the genomes of the main Scedosporium species as basis for a better understanding of the pathogenic mechanisms of these fungi, and discusses treatment options of infections caused by multidrug resistant microorganisms, such as Scedosporium and Lomentospora species and members of the Rasamsonia argillacea species complex.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29538733     DOI: 10.1093/mmy/myx106

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  7 in total

1.  Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC).

Authors:  Sean X Zhang; N Esther Babady; Kimberly E Hanson; Amanda T Harrington; Paige M K Larkin; Sixto M Leal; Paul M Luethy; Isabella W Martin; Preeti Pancholi; Gary W Procop; Stefan Riedel; Seyedmojtaba Seyedmousavi; Kaede V Sullivan; Thomas J Walsh; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

Review 2.  Update on Respiratory Fungal Infections in Cystic Fibrosis Lung Disease and after Lung Transplantation.

Authors:  Sabine Renner; Edith Nachbaur; Peter Jaksch; Eleonora Dehlink
Journal:  J Fungi (Basel)       Date:  2020-12-21

3.  ELISA Test for the Serological Detection of Scedosporium/Lomentospora in Cystic Fibrosis Patients.

Authors:  Leire Martin-Souto; Idoia Buldain; Maialen Areitio; Leire Aparicio-Fernandez; Aitziber Antoran; Jean-Philippe Bouchara; Maria Teresa Martin-Gomez; Aitor Rementeria; Fernando L Hernando; Andoni Ramirez-Garcia
Journal:  Front Cell Infect Microbiol       Date:  2020-11-26       Impact factor: 5.293

Review 4.  Managing Fungal Infections in Cystic Fibrosis Patients: Challenges in Clinical Practice.

Authors:  Lauren C Magee; Mariam Louis; Vaneeza Khan; Lavender Micalo; Nauman Chaudary
Journal:  Infect Drug Resist       Date:  2021-03-22       Impact factor: 4.003

5.  Multilocus Sequence Typing Reveals Extensive Genetic Diversity of the Emerging Fungal Pathogen Scedosporium aurantiacum.

Authors:  Azian Harun; Alex Kan; Katharina Schwabenbauer; Felix Gilgado; Haybrig Perdomo; Carolina Firacative; Heidemarie Losert; Sarimah Abdullah; Sandrine Giraud; Josef Kaltseis; Mark Fraser; Walter Buzina; Michaela Lackner; Christopher C Blyth; Ian Arthur; Johannes Rainer; José F Cano Lira; Josep Guarro Artigas; Kathrin Tintelnot; Monica A Slavin; Christopher H Heath; Jean-Philippe Bouchara; Sharon C A Chen; Wieland Meyer
Journal:  Front Cell Infect Microbiol       Date:  2021-12-27       Impact factor: 5.293

Review 6.  Pneumocystis jirovecii in Patients With Cystic Fibrosis: A Review.

Authors:  Pierre Bonnet; Solène Le Gal; Enrique Calderon; Laurence Delhaes; Dorothée Quinio; Florence Robert-Gangneux; Sophie Ramel; Gilles Nevez
Journal:  Front Cell Infect Microbiol       Date:  2020-09-29       Impact factor: 5.293

7.  A retrospective 'real-world' cohort study of azole therapeutic drug monitoring and evolution of antifungal resistance in cystic fibrosis.

Authors:  M Di Paolo; L Hewitt; E Nwanko; M Ni; A Vidal-Diaz; M C Fisher; D Armstrong-James; A Shah
Journal:  JAC Antimicrob Resist       Date:  2021-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.